FDA is updating its advice to manufacturers of COVID-19 Vaccines (2024-2025 Formula). The agency has determined that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 Formula) is the KP.2 strain, if feasible.
FDA Biologics
4,811 posts
FDA Biologics
@FDACBER
Latest information from the Center for Biologics Evaluation and Research. Contact us at 1-800-835-4709 or [email protected].
fda.gov/privacy
- Replying to @FDACBERFDA does not anticipate that a change to KP.2 will delay the availability of the vaccines for the United States.
- FDA is investigating reports of T-cell malignancies, including chimeric antigen receptor (CAR) positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
- Replying to @FDACBERThis change is based on the most current available data, along with the recent rise in cases of COVID-19 in areas of the country, and is intended to ensure that the COVID-19 vaccines (2024-2025 Formula) more closely match circulating SARS-CoV-2 strains.
- Join us for FDA's Center for Biologics Evaluation and Research town hall livestreaming on FDA YouTube, X @US_FDA and Facebook channels tomorrow at 1 pm ET. FDA leaders will discuss an evidence-based approach to COVID vaccination. youtube.com/live/jbRGlEsbK…
- Trials vs. real world evidence? The answer to that is both. We will always have a place for controlled clinical studies, but we will also leverage the incredible promise of real world data. Here's more from yesterday's FDA Cell and Gene Therapy Roundtable. x.com/US_FDA/status/…
00:00LIVE NOW: FDA's Cell and Gene Therapy Roundtable Captions available here: bit.ly/4dQaNaz x.com/i/broadcasts/1… - FDA/CBER is announcing a date change to the May 16 VRBPAC meeting. The committee will now meet on June 5 to discuss & make recommendations on the strain(s) to be included in the 2024-2025 Formula for COVID-19 vaccines. fda.gov/advisory-commi…
- Vaccines help children lead happy and healthy lives, but declining coverage since the pandemic is leaving millions of children at risk of preventable diseases. It's time to catch up and recommit to making basic immunization accessible for all. #NIIW #Vaccines #biologics #FDA
- #FDAapproves cell-based gene therapy to treat adults with relapsed or refractory multiple #myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti- CD38 monoclonal antibody.fda.gov/vaccines-blood…
- August is National #Immunization Awareness Month. Have questions regarding some of the vaccine products @FDACBER regulates. Click here for answers. fda.gov/vaccines-blood…
- #FDAapproves first cell-based #genetherapy to treat adults and children with Beta-thalassemia who require regular #bloodtransfusions fda.gov/media/160994/d…
- NEW: #FDA has released its final guidance for industry regarding human #GeneTherapy products incorporating human genome editing. Read the full guidance document for more information.
- Replying to @FDACBERThe new date will allow for additional time to obtain surveillance data and other information so the VRBPAC will have more up-to-date information when discussing and making recommendations.
